Stuart A. Weinzimer, United States of America
Yale University Pediatric EndocrinologyPresenter of 1 Presentation
DEBATE: In the era of remote visits – do we still need A1c measures - CON
Abstract
Abstract Body
Hemoglobin A1c has been the gold standard metric to assess glycemic control in people with type 1 diabetes since the Diabetes Control and Complications Trial and has subsequently been adopted to other forms of diabetes, as well as for the diagnosis of diabetes. However, the rapidly increasing use of continuous glucose monitoring (CGM) has enabled clinicians to assess metrics of glycemia more directly; and with the growing popularity of telemedicine, driven most urgently in the past year by the COVID pandemic, the role of A1c as a clinically important measure has been questioned. In this brief debate, we will discuss the relative merits and limitations of A1c and CGM, and whether continuing use of A1c measurement in clinical care is still warranted.